Skip to main content
. Author manuscript; available in PMC: 2019 May 12.
Published in final edited form as: Nat Chem Biol. 2018 Nov 12;14(12):1099–1108. doi: 10.1038/s41589-018-0155-8

Figure 5.

Figure 5.

Effects of ABHD12 inhibition on mouse auditory capacity and brain lyso-PS content in vivo. (a, b) Auditory startle test results for (a) ABHD12(+/+) versus (ABHD12(−/−) mice or (b) mice treated daily for four weeks with vehicle, DO264, or (S)-DO271 (30 mg/kg, p.o.). (c) Brain lyso-PS and PS content from mice treated daily for four weeks with vehicle, DO264, or (S)-DO271 (30 mg/kg, p.o.). The lyso-PS content of brain tissue from ABHD12(+/+) and ABHD12(−/−) mice were included for comparison. Data represent average values ± SEM. For a, b, n = 9, 10, 8, 11, and 15 mice for vehicle, DO264, (S)-DO271, ABHD12(+/+) and ABHD12(−/−) group respectively. For c, n = 5mice per group. * p < 0.05; ** p < 0.01; *** p < 0.001 (Two-sided Student’s t-test performed relative to vehicle-treated mice except for the ABHD12(−/−) data, which were compared to the ABHD12(+/+) data). The p-values and other lipid species measured for c are provided in Supplementary Table 4.